House committee holds hearing on rising price of drug-injecting device
The House Committee on Oversight and Government Reform yesterday held a hearing on the rising price of a device used to inject the drug epinephrine to treat severe allergic reactions. While the EpiPen Auto-Injector has been on the market since 1988, the price for a two-pack of the devices has increased more than 500% over the past decade, according to the committee. Witnesses at the hearing included Heather Bresch, the CEO of Mylan Inc., which acquired the product in 2007; and Doug Throckmorton, deputy director of the Food and Drug Administration’s Center for Drug Evaluation and Research. According to Throckmorton, there are currently no FDA-approved generic epinephrine auto-injectors.
Related News Articles
Headline
The Senate Committee on Health, Education, Labor and Pensions today held the second in a series of hearings on the cost of prescription drugs. “We…
Headline
The Senate Finance Committee today held a hearing on issues impacting health care costs and coverage. Witnesses included former Centers for Medicare &…
Headline
President Trump Friday signed into law the FDA Reauthorization Act (H.R. 2430). The bill reauthorizes and amends four FDA user fee programs under which…
Headline
The average monthly premium for a basic Medicare Part D prescription drug plan in 2018 is estimated to be $33.50 per month – or approximately $1.20 less…
Headline
The Senate yesterday voted 94-1 to approve the FDA Reauthorization Act (H.R. 2430), sending the legislation to the president for his signature. The bill…
Headline
Senate Democratic Leader Charles Schumer and House Democratic Leader Nancy Pelosi today unveiled an economic plan focused on improving wages, lowering costs…